CritiTech Signs R&D Contract

This fall, CritiTech, Inc., a Lawrence-based HBC spin-off company, signed its first R&D contract with a major drug company. The company will employ its patented technology to develop a drug-laden coating for cardiac stents implanted in arteries during an angioplasty. If the coating proves successful in addressing the problem of arterial inflammation associated with stents, it could thrust CritiTech into the thick of a very lucrative market.

"This represents a great start for the company," said CritiTech CEO Doug Johnson. "It stands to really put us on the map."

But CritiTech isn't resting on these recent laurels. The company just signed a letter of intent for an R&D contract for the recrystallization of drugs as fine particles for the trans-dermal patch market. (Some material was provided by Mark Fagan with the Lawrence Journal World.)